BelaCarD Study (AMaRC 19-02)

This is a phase I/II open label single arm clinical study. Patients with Relapsed/Refractory Multiple Myeloma who have had 1 to 3 prior lines of treatment, will receive Belantamab Mafodotin in combination with carfilzomib and dexamethasone. (BelaCarD)

There will be two phases in the study. The first, safety, run-in phase will consist of 10 patients. After the 10th evaluable patient has completed the 1st cycle, the trial management committee (TMC) will hold a meeting to assess whether or not there are any safety concerns at that dosing schedule. Provided that no more than 4 patients experience a grade 4, treatment-emergent toxicity, and subject to the confirmatory advice from the Data Safety and Monitoring Committee (DSMC), the expansion phase will commence at the same treatment dose and schedule.

For more information please visit

Project Information


Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)




Other (specify below)

End date:

Can this be done remotely?


Parts of research done:

Literature review

Positions Available:

Addition of sites for study recruitment


Data Collector

Current Funding:

GlaxoSmithKline (GSK)

Prospective researchers receive:


  • Twitter

Project owner

Hang Quach

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.




VIC. 3002



0424 730 627

ABN: 77 640 321 295


  • Twitter
  • White Facebook Icon
  • White Instagram Icon
  • LinkedIn - White Circle